strontium-89

strontium-89

Radiation oncology A beta-emitting bone-seeking radioisotope–T1⁄2 50.4 days, used to manage pain in Pts with diffuse bone metastases–eg, with end-stage breast or prostate CA for whom pain medication may be ineffective
References in periodicals archive ?
We have been working hard to commercialize both our Strontium-89 products.
The company said, "We have been working hard to commercialize both our Strontium-89 products.
The isotopes produced include Molybdenum-99 (Mo-99), Iodine-131 (I-131), Xenon-133 (Xe-133) and Strontium-89 (Sr-89).
M2 EQUITYBITES-March 19, 2018-Q Biomed Inc submits filing with US FDA for new manufacturing facility for Strontium-89
M2 PHARMA-March 19, 2018-Q Biomed Inc submits filing with US FDA for new manufacturing facility for Strontium-89
Kluge et al., "Fast, low-level detection of strontium-90 and strontium-89 in environmental samples by collinear resonance ionization spectroscopy," Spectrochrmrca Acra, vol.
Two cases of extravasation have been reported secondary to strontium-89 and yttrium -90-ibritumomab, a radiolabeled monoclonal antibody (4, 5).
Radionuclide therapy, in the form of systemic strontium-89 therapy, may be useful in the palliation of CRPC when multiple skeletal sites are involved in carefully selected patients.
Kuroda, "Strontium-89 for prostate cancer with bone metastases: the potential of cancer control and improvement of overall survival," Annals of Nuclear Medicine, vol.
Strontium-89 ([sup.89]Sr) is administered as an IV injection and is beta emitter with a half-life of 50.5 days.
Argiro et al., "Gamma camera imaging of osseous metastatic lesions by strontium-89 bremsstrahlung," European Journal of Nuclear Medicine, vol.
Several [beta]-emitting radiopharmaceuticals (strontium-89, 153Sm-EDTMP, and Re-186 HEDP) are approved for palliation of pain caused by bone metastases from prostate cancer.